There is a large variability regarding the definition and choice of primary endpoints in phase 2 and phase 3 multimodal rectal cancer trials, resulting in inconsistency and difficulty of data interpretation. Also, surrogate properties of early and intermediate endpoints have not been systematically assessed. We provide a comprehensive review of clinical and surrogate endpoints used in trials for non-metastatic rectal cancer. The applicability, advantages, and disadvantages of these endpoints are summarised, with recommendations on clinical endpoints for the different phase trials, including limited surgery or non-operative management for organ preservation. We discuss how early and intermediate endpoints, including patient-reported outcomes and involvement of patients in decision making, can be used to guide trial design and facilitate consistency in reporting trial results in rectal cancer.

Fokas, E., Glynne-Jones, R., Appelt, A., Beets-Tan, R., Beets, G., Haustermans, K., Marijnen, C., Minsky, B. D., Ludmir, E., Quirke, P., Sebag-Montefiore, D., Garcia-Aguilar, J., Gambacorta, M. A., Valentini, V., Buyse, M., Rodel, C., Outcome measures in multimodal rectal cancer trials, <<THE LANCET ONCOLOGY>>, 2020; 21 (5): e252-e264. [doi:10.1016/S1470-2045(20)30024-3] [http://hdl.handle.net/10807/198624]

Outcome measures in multimodal rectal cancer trials

Gambacorta, M. A.;Valentini, V.;
2020

Abstract

There is a large variability regarding the definition and choice of primary endpoints in phase 2 and phase 3 multimodal rectal cancer trials, resulting in inconsistency and difficulty of data interpretation. Also, surrogate properties of early and intermediate endpoints have not been systematically assessed. We provide a comprehensive review of clinical and surrogate endpoints used in trials for non-metastatic rectal cancer. The applicability, advantages, and disadvantages of these endpoints are summarised, with recommendations on clinical endpoints for the different phase trials, including limited surgery or non-operative management for organ preservation. We discuss how early and intermediate endpoints, including patient-reported outcomes and involvement of patients in decision making, can be used to guide trial design and facilitate consistency in reporting trial results in rectal cancer.
2020
Inglese
Fokas, E., Glynne-Jones, R., Appelt, A., Beets-Tan, R., Beets, G., Haustermans, K., Marijnen, C., Minsky, B. D., Ludmir, E., Quirke, P., Sebag-Montefiore, D., Garcia-Aguilar, J., Gambacorta, M. A., Valentini, V., Buyse, M., Rodel, C., Outcome measures in multimodal rectal cancer trials, <<THE LANCET ONCOLOGY>>, 2020; 21 (5): e252-e264. [doi:10.1016/S1470-2045(20)30024-3] [http://hdl.handle.net/10807/198624]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/198624
Citazioni
  • ???jsp.display-item.citation.pmc??? 15
  • Scopus 61
  • ???jsp.display-item.citation.isi??? 56
social impact